Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma
Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma
复制标题
DOI：
10.1007/s12328-017-0785-5
复制
发表时间：
2017-12-01
影响因子：
1
通讯作者：
Ohira, Hiromasa
中科院分区：
文献类型：
--
作者：
Hashimoto, Minami;Hikichi, Takuto;Ohira, Hiromasa
腹部超音波检查发现一个67岁男性糖尿病患者的胰脏肿块。内视镜超音波引导下细针穿刺导致组织学诊断为腺泡细胞癌。根据肝脏和淋巴结中的多个转移病灶以及脾静脉浸润的结果，确定临床分期为IVb。由于患者不适合手术，因此接受了改良FOLFIRINOX化疗。在没有任何严重不良事件的情况下，进行了12个疗程的化疗，导致原发灶和转移灶明显缩小。结果被判定为部分缓解，甚至在引入化疗后9个月仍保持。该病例的结果表明，改良FOLFIRINOX治疗胰腺腺泡细胞癌安全有效。
Abdominal ultrasonography revealed a pancreatic mass in a 67-year-old man with diabetes mellitus. Endoscopic ultrasound-guided fine needle aspiration led to the histological diagnosis of acinar cell carcinoma. The clinical stage was determined to be IVb based on findings of multiple metastatic lesions in the liver and lymph nodes, as well as splenic vein infiltration. Because the patient was not a surgical candidate, he underwent chemotherapy with modified FOLFIRINOX. In the absence of any severe adverse events, 12 courses of chemotherapy were delivered, resulting in marked shrinkage of both the primary and metastatic lesions. The outcome was judged to be a partial response, which was maintained even 9 months from the introduction of the chemotherapy. The results of this case suggest that modified FOLFIRINOX is safe and effective in the treatment of pancreatic acinar cell carcinoma.